on Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics to Announce New IL-17 Antagonist Development
Protagonist Therapeutics, based in Newark, California, will hold a conference call and webcast to introduce its new oral peptide IL-17 antagonist development candidate. This announcement will take place on Thursday, November 21st at 4:30 pm ET. The event will also present results from in vitro and pre-clinical proof-of-concept studies.
Protagonist Therapeutics is recognized for its late-stage biopharmaceutical developments. Currently, the company is advancing two novel peptides in Phase 3 clinical trials. The candidate icotrokinra, licensed to Johnson & Johnson, targets IL-23-mediated diseases like psoriasis. Another candidate, rusfertide, is focused on polycythemia vera under collaboration with Takeda Pharmaceuticals.
Additional information about the company's endeavors and drug candidates is available on the Protagonist Therapeutics website.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Protagonist Therapeutics, Inc. news